α-Synuclein aggregates in corticostriatal terminals impair glutamatergic transmission in the absence of neurodegeneration
Brzozowski, C. F.; Fokakis, Z. N.; Menard, M. A.; Challa, H. V.; Gallardo, I.; Hall, J. D.; Narbert, D.; Millett, M. F.; Hardaway, J. A.; Moehle, M. S.; Volpicelli-Daley, L. A.
Show abstract
Substantia nigra pars compacta dopamine neuron loss and Lewy pathology, aggregates of -synuclein, characterize Parkinsons disease and Dementia with Lewy Bodies. Lewy pathology localizes to cortical neurons, and is found as Lewy neurites in the striatum, but its effects on excitatory synaptic function are just beginning to be understood. Corticostriatal projections regulate motor and cognitive behaviors impaired in these disorders. Here, -synuclein aggregation was induced in mouse M2 cortex, a vulnerable region in human disease. Early after initiation, aggregates localized to corticostriatal vesicular glutamate transporter 1 (vGLUT1)-positive terminals, with sparing of spiny projection neuron (SPN) soma, and dopamine terminals and neurons. Corticostriatal presynaptic aggregates significantly impaired glutamatergic transmission, without overt cortical neuron loss, and were associated with decreased synaptic density and volume. Thus, formation of presynaptic -synuclein aggregates impairs corticostriatal function without degeneration of cortical neurons or striatal dopamine terminals, suggesting pathologic -synuclein is sufficient for synaptic loss. Our findings also point to early synaptic dysfunction as a therapeutic target in Lewy body diseases.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson's disease mouse model 94%
- Hippocampal subfield vulnerability to α-synuclein pathology precedes neurodegeneration and cognitive dysfunction 94%
- Lipidomic Profiling Reveals Shared and Distinct Pathological Signatures in Sporadic Parkinson's Disease and GBA Mutation Carriers: Implications for Disease Mechanisms 94%
Similar papers in this journal
- Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model 95%
- Single-cell sequencing of the human midbrain reveals glial activation and a neuronal state specific to Parkinson's disease 94%
- Data-driven modelling of tau pathology reveals distinct progressive supranuclear palsy subtypes 94%
Similar papers in this journal
- Knockout of Rab27b exacerbates neuropathology in alpha-synuclein mouse models 95%
- Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and Dementia with Lewy bodies 95%
- Genome-wide association, Mendelian Randomization and polygenic risk score studies converge on a role of beta-amyloid and APOE locus in Parkinson disease 94%
Similar papers in this journal
- Depopulation of α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson disease model 96%
- TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy 94%
- Nuclear depletion of RNA binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis 94%
Similar papers in this journal
- Neuropathology in an α-synuclein preformed fibril mouse model occurs independent of the Parkinson's disease-linked lysosomal ATP13A2 protein 94%
- A double-hit in vivo model of GBA1 viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration 94%
- Pathological α-Synuclein Perturbs Nuclear Integrity 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.